The Application of Breviscapine on Graft Restenosis in Coronary Artery Bypass Grafting
-
摘要:
目的 通过临床对照研究,观察灯盏乙素对冠状搭桥术后静脉桥再狭窄的作用。 方法 根据入选和排除标准纳入冠脉搭桥术后患者64例,随机平均分2组(n = 32),对照组患者术后口服常规药物,治疗组除常规药物外,增加灯盏花素片,术后3个月、6个月多层计算机断层血管造影(MSCTA)来检测静脉桥,评估静脉桥再狭窄,2组对比分析。 结果 3和6个月后,灯盏乙素组静脉桥再狭窄程度低于对照组,差异有统计学意义(P < 0.05)。 结论 口服灯盏乙素有助于减轻冠脉搭桥后静脉桥再狭窄。 Abstract:Objective To explore the protective effect of breviscapine on graft vein grafting in the patients who underwent Coronary Artery Bypass Graft (CABG). Methods According to the inclusion criteria and exclusion criteria, 64 patients entered the study and were randomly divided into two groups (n = 32). Group A was the control group, in which patients took oral routine drugs including aspirin, clopidogrel and atorvastatin; Group B was the treatment group, in which patients took oral routine drugs + breviscapine. The rate of graft stenosis was examined by Multi-slics Computed Tomography Angiography (MSCTA) 3 months and 6 months after CABG. Results The rate of graft stenosis in the treatment group was significantly lower than that in the control group 3 and 6 months after CABG (P < 0.05). Conclusion Breviscapine has a protective effect on graft veins in patients who underwent CABG. -
Key words:
- Coronary artery bypass graft /
- Graft vein /
- Restenosis /
- Breviscapine /
- Inhibit
-
表 1 2组患者基本临床资料比较[(
$\bar x \pm s$ )/n(%)]Table 1. Compare clinic data of 2 groups [(
$\bar x \pm s$ )/n(%)]临床资料 对照组
(n = 32)灯盏乙素组
(n = 32)t/χ2 P 年龄(岁) 59.7 ± 4.8 59.5 ± 8.6 0.151 0.861 男性 17(53.1) 19(59.4) 0.011 0.45 身高(cm) 166.5 ± 7.8 166.8 ± 8.3 −0.142 0.875 体重(kg) 71.1 ± 10.9 72.7 ± 11.5 −0.968 0.335 高血压病 21(65.6) 20(62.5) 0.311 0.341 糖尿病 10(31.3) 12(37.5) 0.315 0.347 高脂血症 9(28.1) 11(34.3) 0.434 0.312 吸烟史 15(46.9) 17(53.1) 0.276 0.336 家族史 14(43.8) 15(46.9) 0.013 0.519 左心室射血分数(%) 45.3 ± 8.4 46.4 ± 9.6 −0.812 0.451 心肌梗死 9(28.1) 10(31.2) 0.034 0.511 表 2 静脉桥内径比较(
$ \bar x \pm s$ )Table 2. Compare the inner diameter of graft vein (
$\bar x \pm s $ )组别 术后3月(mm) 术后6月(mm) 对照组 5.0 ± 0.5 4.6 ± 0.4 灯盏乙素组 5.1 ± 0.6* 4.9 ± 0.6* 与对照组比较,*P < 0.05。 -
[1] Destephan C M,Schneider D J. Antiplatelet therapy for patients undergoing coronary artery bypass surgery[J]. Kardiol Pol,2018,76(6):945-952. doi: 10.5603/KP.a2018.0111 [2] Gao Ge,Zheng Zhe,Pi Yi,et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center,randomized,controlled trial[J]. J Am Coll Cardiol,2010,56(20):1639-1643. doi: 10.1016/j.jacc.2010.03.104 [3] Sousa-Uva M,Neumann F J,Ahlsson A,et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur J Cardiothorac Surg,2019,55(1):4-90. doi: 10.1093/ejcts/ezy289 [4] Velazquez E J,Lee K L,Jones R H,et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J]. N Engl J Med,2016,374(16):1511-1520. doi: 10.1056/NEJMoa1602001 [5] 张浒,钟佳冀,黄宏波,等. 灯盏花素对冠脉搭桥术移植静脉保护作用的实验[J]. 昆明医科大学学报,2019,40(11):26-29. doi: 10.3969/j.issn.1003-4706.2019.11.005 [6] Wang X,Tian M,Zheng Z,et al. Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery[J]. Am Heart J,2019,210(40):75-80. [7] Spadaccio C,Benedetto U. Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease:Quo vadis? -A review of the evidences on coronary artery disease[J]. Ann Cardiothorac Surg,2018,7(4):506-515. doi: 10.21037/acs.2018.05.17 [8] Khan Y,Cheema M A,Abdullah H M A,et al. Great saphenous vein stump:A risk factor for superficial/deep venous thrombosis and an indication for prophylactic anticoagulation? - A retrospective analysis[J]. Community Hosp Intern Med Perspect,2019,9(6):473-476. doi: 10.1080/20009666.2019.1655626 [9] Mckavanagh P,Yanagawa B,Zawadowski G,et al. Management and prevention of saphenous vein graft failure:A review[J]. Cardiol Ther,2017,6(2):203-223. doi: 10.1007/s40119-017-0094-6 [10] Gaudino M,Benedetto U,Fremes S,et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery[J]. N Engl J Med,2018,378(22):2069-2077. doi: 10.1056/NEJMoa1716026 [11] Cao B J,Wang X W,Zhu L,et al. Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts[J]. J Mol Cell Cardiol,2019,128(3):134-144. [12] Cao B J,Zhu L,Wang X W,et al. MicroRNA-365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts[J]. IUBMB Life,2019,71(7):908-916. doi: 10.1002/iub.2022 [13] Wadey K,Lopes J,Bendeck M,et al. Role of smooth muscle cells in coronary artery bypass grafting failure[J]. Cardiovasc Res,2018,114(4):601-610. doi: 10.1093/cvr/cvy021 [14] Muto A,Model L,Ziegler,K,et al. Mechanisms of vein graft adaptation to the arterialcirculation:Insights into the neointimal algorithm and management strategies[J]. Circ J,2010,74(8):1501-1512. doi: 10.1253/circj.CJ-10-0495 [15] 国家药典委员会. 中国药典[M]. 第二部. 北京: 中国医药科技出版社, 2005: 100. [16] Wen L,He T,Yu AX,et al. Breviscapine:A Review on its Phytochemistry,Pharmacokinetics and Therapeutic Effects[J]. Am J Chin Med,2021,49(6):1369-1397. doi: 10.1142/S0192415X21500646 [17] Chen Z,Wang C,Liu Y,et al. Protective effects of medicinal plant breviscapine on postcerebral hemorrhage in rats[J]. J Integr Neurosci,2020,19(1):101-109. doi: 10.31083/j.jin.2020.01.1253 [18] Li Y,Li S,Li D. Breviscapine alleviates cognitive impairments induced by transient cerebral ischemia/reperfusion through its anti-inflammatory and anti-oxidant properties in a rat model[J]. ACS Chem Neurosci,2020,11(24):4489-4498. doi: 10.1021/acschemneuro.0c00697 [19] He M,Xue Z M,Li J,et al. Breviscapine inhibits high glucose-induced proliferation and migration of cultured vascular smooth muscle cells of rats via suppressing the erk1/2 mapk signaling pathway[J]. Acta Pharmacol Sin,2012,33(5):606-614. doi: 10.1038/aps.2012.6